People · Operator

Kenneth J. Lynn

Named in public records as an officer, director or promoter · active 2010–2011 · Biotechnology

1
Companies
6
Filings
$67.5M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Newlink Genetics CorpBiotechnologySeries B$67.5M$411.2M2010
Operator network

Kenneth J. Lynn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Paul R. Edick · 2 companies · 1 sharedPaul R. EdickCharles Link, M.D. · 1 companies · 1 sharedCharles Link, M.D.David J. Lundquist · 1 companies · 1 sharedDavid J. LundquistErnest H. Talarico, III · 1 companies · 1 sharedErnest H. Talaric…Ernest Talarico, III · 1 companies · 1 sharedErnest Talarico, …Gordon H. Link · 1 companies · 1 sharedGordon H. LinkJoseph J. Saluri · 1 companies · 1 sharedJoseph J. SaluriKenneth Lynn · 1 companies · 1 sharedKenneth LynnNicholas Vahanian, M.D. · 1 companies · 1 sharedNicholas Vahanian…Paul J. Edick · 1 companies · 1 sharedPaul J. EdickSarah J. Alexander, M.D. · 1 companies · 1 sharedSarah J. Alexande…Tom H. Raffin, M.D. · 1 companies · 1 sharedTom H. Raffin, M.…Tom Raffin, M.D. · 1 companies · 1 sharedTom Raffin, M.D.Newlink Genetics Corp · $67.5M raisedNewlink Genetics CorpKenneth J. LynnKL
Kenneth J. Lynn Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Kenneth J. Lynn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Paul R. Edick12
Ernest H. Talarico, III11
Joseph J. Saluri11
Nicholas Vahanian, M.D.11
Gordon H. Link11
David J. Lundquist11
Sarah J. Alexander, M.D.11
Tom H. Raffin, M.D.11
Charles Link, M.D.11
Paul J. Edick11
Kenneth Lynn11
Ernest Talarico, III11
Tom Raffin, M.D.11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.